These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 23457302)
21. PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice. Paardekooper Overman J; Yi JS; Bonetti M; Soulsby M; Preisinger C; Stokes MP; Hui L; Silva JC; Overvoorde J; Giansanti P; Heck AJ; Kontaridis MI; den Hertog J; Bennett AM Mol Cell Biol; 2014 Aug; 34(15):2874-89. PubMed ID: 24865967 [TBL] [Abstract][Full Text] [Related]
22. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase. Miura K; Wakayama Y; Tanino M; Orba Y; Sawa H; Hatakeyama M; Tanaka S; Sabe H; Mochizuki N Oncogene; 2013 Nov; 32(45):5292-301. PubMed ID: 23318428 [TBL] [Abstract][Full Text] [Related]
23. Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2. Zhang RY; Yu ZH; Chen L; Walls CD; Zhang S; Wu L; Zhang ZY J Biol Chem; 2020 May; 295(18):6187-6201. PubMed ID: 32188694 [TBL] [Abstract][Full Text] [Related]
24. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome. Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529 [TBL] [Abstract][Full Text] [Related]
25. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers. Shen D; Chen W; Zhu J; Wu G; Shen R; Xi M; Sun H Eur J Med Chem; 2020 Mar; 190():112117. PubMed ID: 32061959 [TBL] [Abstract][Full Text] [Related]
26. LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity. Tajan M; Batut A; Cadoudal T; Deleruyelle S; Le Gonidec S; Saint Laurent C; Vomscheid M; Wanecq E; Tréguer K; De Rocca Serra-Nédélec A; Vinel C; Marques MA; Pozzo J; Kunduzova O; Salles JP; Tauber M; Raynal P; Cavé H; Edouard T; Valet P; Yart A Proc Natl Acad Sci U S A; 2014 Oct; 111(42):E4494-503. PubMed ID: 25288766 [TBL] [Abstract][Full Text] [Related]
27. Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2. LaRochelle JR; Fodor M; Xu X; Durzynska I; Fan L; Stams T; Chan HM; LaMarche MJ; Chopra R; Wang P; Fortin PD; Acker MG; Blacklow SC Biochemistry; 2016 Apr; 55(15):2269-77. PubMed ID: 27030275 [TBL] [Abstract][Full Text] [Related]
29. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study. Li HL; Ma Y; Zheng CJ; Jin WY; Liu WS; Wang RL J Biomol Struct Dyn; 2018 Nov; 36(14):3856-3868. PubMed ID: 29125030 [TBL] [Abstract][Full Text] [Related]
31. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227 [TBL] [Abstract][Full Text] [Related]
32. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation. Liu WS; Wang RR; Li WY; Rong M; Liu CL; Ma Y; Wang RL J Biomol Struct Dyn; 2020 Jun; 38(9):2509-2520. PubMed ID: 31258001 [TBL] [Abstract][Full Text] [Related]
33. SHP2 sails from physiology to pathology. Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048 [TBL] [Abstract][Full Text] [Related]
34. The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain. van Vlimmeren AE; Voleti R; Chartier CA; Jiang Z; Karandur D; Humphries PA; Lo WL; Shah NH Proc Natl Acad Sci U S A; 2024 Jul; 121(30):e2407159121. PubMed ID: 39012820 [TBL] [Abstract][Full Text] [Related]
35. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy. Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432 [TBL] [Abstract][Full Text] [Related]
36. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. Keilhack H; David FS; McGregor M; Cantley LC; Neel BG J Biol Chem; 2005 Sep; 280(35):30984-93. PubMed ID: 15987685 [TBL] [Abstract][Full Text] [Related]
37. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. Marin TM; Keith K; Davies B; Conner DA; Guha P; Kalaitzidis D; Wu X; Lauriol J; Wang B; Bauer M; Bronson R; Franchini KG; Neel BG; Kontaridis MI J Clin Invest; 2011 Mar; 121(3):1026-43. PubMed ID: 21339643 [TBL] [Abstract][Full Text] [Related]